188 related articles for article (PubMed ID: 38097412)
21. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
[TBL] [Abstract][Full Text] [Related]
22. Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Pernas S; Tolaney SM
JCO Oncol Pract; 2021 Jun; 17(6):320-330. PubMed ID: 34111378
[TBL] [Abstract][Full Text] [Related]
23. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
Kunte S; Abraham J; Montero AJ
Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
[TBL] [Abstract][Full Text] [Related]
24. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X; Hooper M; Borlagdan JP; Palumbo A
Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
[TBL] [Abstract][Full Text] [Related]
25. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
26. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C; Milano M; Brambilla M; Mennitto A; Maggi C; Cona MS; Prisciandaro M; Fabbroni C; Celio L; Mariani G; Bianchi GV; Capri G; de Braud F
Crit Rev Oncol Hematol; 2019 Jul; 139():53-66. PubMed ID: 31112882
[TBL] [Abstract][Full Text] [Related]
27. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey N; Sandoval A; Mahtani R
Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
29. Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Gilchrist J
Semin Oncol Nurs; 2024 Feb; 40(1):151547. PubMed ID: 38123401
[TBL] [Abstract][Full Text] [Related]
30. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Kelly CM; Buzdar AU
Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy for metastatic HER2-positive breast cancer.
Bredin P; Walshe JM; Denduluri N
Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
[TBL] [Abstract][Full Text] [Related]
33. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
34. [Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly].
Celik A; Berg T; Knoop AS; Andersson M
Ugeskr Laeger; 2021 Jun; 183(26):. PubMed ID: 34219638
[TBL] [Abstract][Full Text] [Related]
35. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
36. HER2-positive breast cancer: Current and new therapeutic strategies.
Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C
Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
38. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
39. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Oliveira M; Garrigós L; Assaf JD; Escrivá-de-Romaní S; Saura C
Expert Rev Anticancer Ther; 2020 Sep; 20(9):731-741. PubMed ID: 32862744
[TBL] [Abstract][Full Text] [Related]
40. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
